Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment. Our platform is 87% concordant with clinical patient data - a vast improvement over the 3% translational success rate of animals. We’ve demonstrated the ability to model immunotoxicology, immunogen stimulation, and two autoimmune diseases with more on the way. Numerous pharma partners including 3 Fortune 500 companies are already using the platform. We've raised ~$30M from AIX Ventures, Marc Benioff, Jeff Dean, and Y Combinator. With the FDA Modernization Act 3.0 and the FDA's March 2026 validation framework, the regulatory tailwinds only continue to get stronger. The opportunity ahead of the company is generational: build the first scaled engine for generating real human biological data, and use it to fundamentally change how medicines are discovered. The core problem in drug discovery is that there’s no reliable way to know how a compound will behave in a real human immune system before it enters patients. Animal models fail. Cell lines are too reductive. Clinical trials are too late. Parallel Bio has built the missing prediction layer: patient-derived immune organoids that fully recapitulate human immune system function, combined with advanced computation to generate population-scale drug response data. R&D leaders at biotech and pharma companies who see the platform immediately grasp what it means for their pipelines. Your job is to get them to that moment, and close. We have major pharma Fortune 500 partners, validated technology, and a product the market has been waiting for. What we need now is someone to build the global commercial infrastructure to own and scale our process.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Associate degree